[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556496":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":17,"locations":22,"responsibleParty":39,"collaborators":7,"id":41,"slug":7,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":7,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":7,"enrollmentInfo":49,"targetDuration":7,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":7,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Insel Gruppe AG, University Hospital Bern","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"LTOT","Patients with newly prescribed LTOT will be monitored for physiological changes",[13],{"name":14,"affiliation":15,"role":16},"Sabina Guler, PD Dr. med.","Universitätsklinik für Pneumologie, Allergologie und klinische Immunologie, Inselspital Bern","PRINCIPAL_INVESTIGATOR",[18],{"name":14,"role":19,"phone":20,"phoneExt":7,"email":21},"CONTACT","+41 31 66 4 48 92","sabina.guler@insel.ch",[23],{"facility":24,"status":25,"city":26,"state":7,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Inselspital, Bern University Hospital","RECRUITING","Bern","3010","Switzerland","CH",{"type":31,"coordinates":32},"Point",[33,34],7.44744,46.94809,{"lat":34,"lon":33},[37],{"name":38,"role":19,"phone":7,"phoneExt":7,"email":21},"Sabina Guler",{"type":40,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100556496",false,"NCT06525857","Observing Physiological Changes in Patients With Long-term Oxygen Therapy","Observing Physiological Changes in Patients With Long-term Oxygen Therapy Via Optical and Accelerometry Signals","Inclusion Criteria:\n\n* Age ≥ 18-year-old, and\n* Chronic respiratory disease including a) chronic obstructive pulmonary disease, b) interstitial lung disease, c) pulmonary hypertension, d) bronchiectasis, and\n* Prescribed new LTOT due to a chronic respiratory disease with resting and\u002For exertional hypoxemia, and\n* Able to speak\u002Fread\u002Funderstand German or French, and\n* Willing and able to understand and provide signed informed consent\n\nExclusion Criteria:\n\n* Pregnant or lactating women, or\n* Inability to follow the procedures\u002Finstructions of the study (e.g. due to language, psychological disorders, dementia, etc.), or\n* Patients having a subordination link to the investigators, or\n* Patients with isolated nocturnal oxygen therapy or LTOT prescription for a heart disease, sleep associated breathing disorder, neuromuscular disease or lung cancer, or\n* Known participation in another human research project (ClinO\u002FHRO) that may affect the objectives of this study.","ALL","18 Years",{"count":50,"type":51},40,"ESTIMATED","OBSERVATIONAL","In this project, the investigators aim to assess changes of physiological parameters obtained non-invasively through PPG and accelerometry signals between before and during LTOT (long-term oxygen therapy) and investigate if those changes are different in patients with worsening frailty and\u002For improving quality of life.\n\nFor this, they will record optical (PPG) and accelerometry data via a datalogger on 40 patients undergoing LTOT and assess the PPG-derived physiological signals.",[55],"Chronic Respiratory Disease","2024-07-25",{"date":58,"type":59},"2024-07-29","ACTUAL",{"date":61,"type":59},"2024-06-01",{"date":63,"type":51},"2026-01-31",{"name":5,"class":6},1]